Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL27610429 | 0.89 | PIM1 (0.45) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL13204318 | 0.84 | PIM1 (0.54) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL3050825 | 0.78 | SIRT2 (0.56) | PIM1SIRT2AXLCAMKK2KDR | |
| SCHEMBL15799855 | 0.78 | CAMKK2 (0.56) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL5343477 | 0.78 | SIRT2 (0.80) | PIM1SIRT2SIRT1KDRFLT3 | |
| SCHEMBL6081255 | 0.77 | PIM1 (0.47) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL5879226 | 0.77 | FLT3 (0.57) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL17210880 | 0.76 | PIM1 (0.50) | PIM1TGFBR1IKBKEPDPK1TBK1 | |
| SCHEMBL5828027 | 0.75 | PIM1 (0.47) | PIM1SIRT2AXLCAMKK2KDR | |
| SCHEMBL6575546 | 0.75 | PIM1 (0.53) | PIM1TGFBR1IKBKEPDPK1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928465-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| EP-2928465-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| EP-2928466-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-2928466-B1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180325877-A1 | Use of Maleimide Derivatives for Preventing and Treating Cancer | CENTOGENE GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| US-9993463-B2 | Use of maleimide derivatives for preventing and treating cancer | CENTOGENE AG (DE) | 2018-06-12 | — | — | US | disclosed |
| US-9724331-B2 | Use of maleimide derivatives for preventing and treating leukemia | CENTOGENE AG (DE) | 2017-08-08 | — | — | US | disclosed |
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | CENTOGENE AG (DE) | 2015-10-29 | — | — | US | disclosed |
| WO-2014090396-A2 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | CENTOGENE AG (DE) | 2014-06-19 | — | — | WO | disclosed |
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| US-7001906-B2 | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | LES LABORATOIRES SERVIER (FR) | 2006-02-21 | — | — | US | disclosed |
| US-20060004428-A1 | Pyrrolo (3,4-c) carbazole and pyrido (2,3-b) pyrrolo (3,4-e) indole derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2006-01-05 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040152721-A1 | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | LES LABORATOIRES SERVIER (FR) | 2004-08-05 | — | — | US | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
| EP-1409486-A1 | PYRIDO-PYRIDO-PYRROLO PYRROLO-INDOLE AND PYRIDO-PYRROLO PYRROLO CARBAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | LES LABORATOIRES SERVIER (FR) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003002563-A1 | PYRIDO-PYRIDO-PYRROLO PYRROLO-INDOLE AND PYRIDO-PYRROLO PYRROLO CARBAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | LES LABORATOIRES SERVIER (FR) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313882-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING CANCER | MGMT, CBR3, IDH3A | PIM1 3826/4885TGFBR1 2161/4885IKBKE 1806/4885 |
| US-20180325877-A1 | Use of Maleimide Derivatives for Preventing and Treating Cancer | MGMT, IDH3A, CYP3A43 | PIM1 3743/4885TGFBR1 2075/4885IKBKE 1609/4885 |
| US-20040152721-A1 | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | PYM1, PNPO, IDO1 | PIM1 1680/4885TGFBR1 2488/4885IKBKE 2665/4885 |
| US-20150306070-A1 | USE OF MALEIMIDE DERIVATIVES FOR PREVENTING AND TREATING LEUKEMIA | MCL1, NPM1, FLI1 | PIM1 2347/4885TGFBR1 3330/4885IKBKE 802/4885 |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | PIM1 4162/4885TGFBR1 958/4885IKBKE 1645/4885 |
| US-10420754-B2 | Use of maleimide derivatives for preventing and treating cancer | MGMT, IDH3A, CYP3A43 | PIM1 3743/4885TGFBR1 2075/4885IKBKE 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.